J&J’s stock surrenders early gains as weak sales guidance offsets earnings beat

J&J’s stock surrenders early gains as weak sales guidance offsets earnings beat




Medtech and drug company’s 2025 sales guidance is below consensus



Source link

Tagged:

Related News

Popular News

Categories Collection

Recent News